372 related articles for article (PubMed ID: 33058344)
1. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register.
Lepore V; Bosetti C; Santucci C; Iaffaldano P; Trojano M; Mosconi P;
Eur J Neurol; 2021 Feb; 28(2):567-578. PubMed ID: 33058344
[TBL] [Abstract][Full Text] [Related]
2. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Kappos L; Butzkueven H; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S; Trojano M;
Mult Scler; 2018 Jun; 24(7):963-973. PubMed ID: 28554238
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR
Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679
[TBL] [Abstract][Full Text] [Related]
6. Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
Lorefice L; Ferraro OE; Fenu G; Amato MP; Bresciamorra V; Conte A; De Luca G; Ferraro D; Filippi M; Gazzola P; Iaffaldano P; Inglese M; Lus G; Marfia GA; Patti F; Pesci I; Salemi G; Trojano M; Zaffaroni M; Monti MC; Cocco E;
J Neurol; 2024 Apr; 271(4):1630-1637. PubMed ID: 38172380
[TBL] [Abstract][Full Text] [Related]
7. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
8. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis.
Amato MP; Fonderico M; Portaccio E; Pastò L; Razzolini L; Prestipino E; Bellinvia A; Tudisco L; Fratangelo R; Comi G; Patti F; De Luca G; Brescia Morra V; Cocco E; Pozzilli C; Sola P; Bergamaschi R; Salemi G; Inglese M; Millefiorini E; Galgani S; Zaffaroni M; Ghezzi A; Salvetti M; Lus G; Florio C; Totaro R; Granella F; Vianello M; Gatto M; Di Battista G; Aguglia U; Logullo FO; Simone M; Lucisano G; Iaffaldano P; Trojano M
Brain; 2020 Oct; 143(10):3013-3024. PubMed ID: 32935843
[TBL] [Abstract][Full Text] [Related]
9. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study.
Portaccio E; Bellinvia A; Fonderico M; Pastò L; Razzolini L; Totaro R; Spitaleri D; Lugaresi A; Cocco E; Onofrj M; Di Palma F; Patti F; Maimone D; Valentino P; Confalonieri P; Protti A; Sola P; Lus G; Maniscalco GT; Brescia Morra V; Salemi G; Granella F; Pesci I; Bergamaschi R; Aguglia U; Vianello M; Simone M; Lepore V; Iaffaldano P; Filippi M; Trojano M; Amato MP
Brain; 2022 Aug; 145(8):2796-2805. PubMed ID: 35325059
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort.
López-Real AM; Gonzalez I; Solar DM; Oterino A; Costa E; Pato A; Llaneza MA; García-Estévez DA; Rodriguez-Regal A; Rodriguez M; Peña J
Mult Scler Relat Disord; 2023 Jul; 75():104762. PubMed ID: 37229800
[TBL] [Abstract][Full Text] [Related]
11. Worsening of disability caused by relapses in multiple sclerosis: A different approach.
Koch-Henriksen N; Thygesen LC; Sørensen PS; Magyari M
Mult Scler Relat Disord; 2019 Jul; 32():1-8. PubMed ID: 31003200
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials.
Ingwersen J; Masanneck L; Pawlitzki M; Samadzadeh S; Weise M; Aktas O; Meuth SG; Albrecht P
Sci Rep; 2023 Sep; 13(1):15003. PubMed ID: 37696848
[TBL] [Abstract][Full Text] [Related]
13. Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
Bucello S; Annovazzi P; Ragonese P; Altieri M; Barcella V; Bergamaschi R; Bianchi A; Borriello G; Buscarinu MC; Callari G; Capobianco M; Capone F; Cavalla P; Cavarretta R; Cortese A; De Luca G; Di Filippo M; Dattola V; Fantozzi R; Ferraro E; Filippi MM; Gasperini C; Grimaldi LME; Landi D; Re ML; Mallucci G; Manganotti P; Marfia GA; Mirabella M; Perini P; Pisa M; Realmuto S; Russo M; Tomassini V; Torri-Clerici VLA; Zaffaroni M; Zuliani C; Zywicki S; Filippi M; Prosperini L
J Neurol; 2021 Aug; 268(8):2922-2932. PubMed ID: 33616742
[TBL] [Abstract][Full Text] [Related]
14. Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study.
Costa-Frossard França L; Meca Lallana V; Labiano-Fontcuberta A; Blasco R; Monreal E; Martínez Ginés ML; Aguirre C; Sabin Muñoz J; Sainz de la Maza S; Cuello JP; Díaz-Pérez C; Chico García JL; Lozano Ros A; Rodríguez Jorge F; Martínez Martínez S; García Domínguez JM
CNS Drugs; 2024 Mar; 38(3):231-238. PubMed ID: 38418770
[TBL] [Abstract][Full Text] [Related]
15. Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.
Koch MW; Mostert J; Repovic P; Bowen JD; Wolinsky JS; Lublin FD; Strijbis E; Cutter G
Eur J Neurol; 2022 Apr; 29(4):1106-1116. PubMed ID: 34927308
[TBL] [Abstract][Full Text] [Related]
16. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients.
Cavallari M; Palotai M; Glanz BI; Egorova S; Prieto JC; Healy BC; Chitnis T; Guttmann CR
Mult Scler; 2016 Dec; 22(14):1841-1849. PubMed ID: 26920374
[TBL] [Abstract][Full Text] [Related]
17. Relationship between sustained disability progression and functional system scores in relapsing-remitting multiple sclerosis: analysis of placebo data from four randomized clinical trials.
Scott T; Wang P; You X; Mann M; Sperling B
Neuroepidemiology; 2015; 44(1):16-23. PubMed ID: 25634764
[TBL] [Abstract][Full Text] [Related]
18. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.
Liu C; Blumhardt LD
J Neurol Neurosurg Psychiatry; 2000 Apr; 68(4):450-7. PubMed ID: 10727480
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
[TBL] [Abstract][Full Text] [Related]
20. Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases.
Findling O; Rust H; Yaldizli Ö; Timmermans DPH; Scheltinga A; Allum JHJ
Front Neurol; 2018; 9():686. PubMed ID: 30186223
[No Abstract] [Full Text] [Related]
[Next] [New Search]
